ABSTRACT
Objective To analyze the screening results of tumor markers carbohydrate antigen 724 (CA-724), carbohydrate antigen 153 (CA-153), carbohydrate antigen 125 (CA-125), carbohydrate antigen 199 (CA-199) and carcinoembryonic antigen (CEA) in the 45 ~ 60-year-old health examination population in Chengdu area. Methods A total of 2 268 healthy people aged 45 ~ 60 years old living in Chengdu area from May 2019 to August 2020 were selected. Levels of serum tumor markers CA-724, CA-153, CA-125, CA-199 and CEA were detected by electrochemiluminescence. Positive rates of different tumor markers and confirmed diagnosis of malignant tumors were statistically analyzed. People with positive and negative tumor markers were respectively included in the positive group and the negative group, and their serum tumor markers were compared. The screening results of tumor markers in the health examination population of different gender and age, and the diagnostic efficiency of each tumor marker for malignant tumors were analyzed. Results Among the 2 268 healthy people, the positive rates of CA-724, CA-153, CA-125, CA-199 and CEA were 10.05%, 4.98%, 1.10%, 7.01% and 4.76%, respectively. A total of 72 cases were positive for tumor marker detection, with a total positive rate of 3.17% (72/2,268). Among them, 12 cases were diagnosed as early or mid-term tumors by pathology, imaging and other examinations, with a total tumor detection rate of 0.53% (12/2,268), including 8 cases of malignant tumors, with a detection rate of 0.35% (8/2,268). The levels of CA-724, CA-153, CA-125, CA-199 and CEA in the tumor markers positive group were higher than those in the negative group (P<0.05). The CA-125 and CA-199 positive rates in males were lower than those in females, while CEA positive rate was higher in males than in females (P<0.05). Positive rates of CA-153, CA-199 and CEA in different age groups showed statistically significant differences (P<0.05). Positive expression of CA-153 and CA-199 mainly occurred in the 51~60 years old group, and positive expression of CEA mainly occurred in the 45~50 years old group. ROC curve analysis showed that combined detection of CA-724, CA-153, CA-125, CA-199 and CEA had the highest sensitivity, specificity and accuracy in predicting malignant tumors, and the area under the curve was the largest (0.865). Conclusion Tumor markers CA-724, CA-153, CA-125, CA-199 and CEA are highly expressed in the 45 ~ 60-year-old health examination population in Chengdu area, and positive rate of CA-724 is the highest. Levels of tumor markers in people of different gender and age are also different. Joint detection of various tumor markers is conducive to early detection and treatment of the disease, and reduction of deterioration risk.
ABSTRACT
Breast cancer is a common malignant tumor in women,and immunotherapy is one of the treatments with a good clinical prognosis. CA153 can activate immune response as a specific antigen in breast cancer immune response;participate in T cell activation;target binding peptide vaccine;enhance immune response;induce dendritic cell maturation,and eliminate cancer cells in vi-vo. Therefore,CA153 plays an important role in the immune response and treatment of breast cancer,and can be used as a new target for breast cancer immunotherapy.
ABSTRACT
O antígeno CA 15-3 é uma proteína presente no soro utilizado no acompanhamento de mulheres com câncer de mama, essencialmente na detecção de metástases. Os objetivos deste estudo foram avaliar a efetividade e a viabilidade da utilização do marcador tumoral CA 15-3 em cadelas, comparando-se os valores do marcador entre cadelas sem e com neoplasia mamária, avaliando-se alterações nos valores do marcador após a mastectomia, e suas correlações entre o tipo histológico. Foi realizada a quantificação sérica do marcador tumoral CA 15-3 (teste de eletroquimioluminescência), em vinte cadelas hígidas (grupo controle) e vinte cadelas com neoplasia mamária (grupo teste). Os animais com neoplasia tiveram a dosagem do marcador realizada antes e 10 dias após a mastectomia. Ainda, foi realiza a citologia vaginal no momento da mastectomia e foram estabelecidos três grupos de acordo com a fase estral de cada cadela, Diestro, Proestro e Anestro. As massas tumorais foram encaminhadas para exame histopatológico. A avaliação dos dados de citologia vaginal entre os grupos Diestro, Proestro e Anestro pelo teste de ANOVA não demonstrou diferença estatística significativa entre os valores encontrados. E na análise para a comparação dos valores do marcador tumoral com os tipos histológicos de neoplasias, divididas em dois grupos, benignas e malignas, utilizando o teste de Mann-Whitney Rank Sum Test, o teste não demonstrou diferença estatística significativa visto que p>0,05. Os valores encontrados do marcador no grupo controle foram uma média de 0,19+0,39 U/mL, no grupo pré-mastectomia 1,56+0,39 U/mL e pós-mastectomia 0,66+0,27 U/mL. Em análise estatística com a comparação de grupo pré e pós-mastectomia, e do grupo controle com o grupo pré e pós-mastectomia observou-se significância com p< 0,005. Assim, observou-se diferença nos valores do marcador antes e depois da remoção cirúrgica da neoplasia, sugerindo seu possível uso como controle de crescimento tumoral pós-mastectomia individual. Porém há muita variação dos resultados nos diferentes métodos existentes, e não há ainda um padrão dos valores de referência para cada método, sendo necessários mais estudos sobre o uso dos marcadores.(AU)
The CA 15-3 antigen is a protein present in the serum, used to monitor women with breast cancer, mainly in metastatic disease detection. The objective of this study was to evaluate the effectiveness and feasibility of the CA 15-3 tumor marker in dogs, comparing the marker values between dogs with or without breast cancer, to estimate changes in marker values after mastectomy, and their correlation between the histological types. Serum quantification of the tumor marker CA 15-3 (electrochemiluminescence test) was performed in twenty healthy bitches and twenty others with mammary neoplasia. Bitches with cancer had the content of the tracer performed before and 10 days after mastectomy. The vaginal cytology was performed at the moment of the mastectomy, dividing the animals into three different groups (diestrus, proestrus and anestrus). All the mammary tumors were examined histopathologically. The evaluation of the vaginal cytology data of the groups Diestro, Proestro and Anestro by the ANOVA test did not show a statistically significant difference between the values found. In the analysis histological types of tumor marker values of neoplasms, divided into two groups, benign and malignant, using the Mann-Whitney Rank Sum Test, there was no statistical significant difference at p>0.05. The values of the marker in the control group had an average of 0.19+0.39 U/mL, of the pre-mastectomy group 1.56+0.39 U/mL, and of the post-mastectomy group 0.66+0.27 U/mL. The statistic was performed comparing groups pre- and post-mastectomy, and the control group with group pre- and post-mastectomy with a statistical significance p< 0.005 in both tests. There was a difference of marker values before and after surgical removal of the neoplasia, suggesting its possible use in post-mastectomy tumor control. But exist variation of results with the different existing methods, and there will be still a standard reference value for each method.(AU)
Subject(s)
Animals , Female , Dogs , Breast Neoplasms/veterinary , Biomarkers, Tumor/analysis , Dogs/abnormalities , Mucin-1 , ElectrochemotherapyABSTRACT
Objective To investigate the effect of color magnetic resonance imaging (MRI) combined with serum levels of carbohydrate antigen 153 (CA153),carcinoembryonic antigen (CEA) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) on the diagnostic efficacy of breast cancer patients.Methods From December 2015 to December 2017,80 cases of breast cancer in our hospital were selected as the observation group.Another 98 patients with benign breast diseases as control group A,and 94 healthy women as control group B.The serum levels of CA153,CEA and CYFRA21-1in the three groups were measured by electrochemiluminescence and the level of the above serum indexes in patients with different disease stages (stage Ⅰ to Ⅱ,Ⅲ to Ⅳ) in the observation group were compared.The 3 groups were examined by color Doppler high frequency ultrasound.The specificity,sensitivity and accuracy of color Doppler ultrasound combined with serum CA153,CEA and CYFRA21-1 or detecting alone in the diagnosis of breast cancer analyzed.Results There were significant differences in the levels of serum CA153,CEA and CYFRA21-1 in the 3 groups (P ＜0.05),and the level of serum CA153,CEA and CYFRA21-1 in the observation group was higher than that in the control group A and the control group B (P ＜ 0.05).The levels of serum CA153,CEA and CYFRA21-1 in patients in stage Ⅲ to Ⅳ of the observation group were higher than those in patients in stage Ⅰ to Ⅱ (P ＜ 0.05).The sensitivity and accuracy of color Doppler ultrasound combined with serum CA153,CEA and CYFRA21-1 in the diagnosis of breast cancer were 96.25％ (77/80) and 84.93％ (231/272),respectively,which were all higher than those of serum CA153,CEA and CYFRA21-1 alone (P ＜ 0.05).And the sensitivity of combined diagnosis was higher than that of color Doppler high frequency ultrasound alone (P ＜ 0.05).Conclusions Color Doppler ultrasound combined with serum levels of CA153,CEA and CYFRA21-1 can significantly improve the sensitivity and accuracy of breast cancer diagnosis,reduce the risk of missed diagnosis,and provide a strong basis for diagnosis and treatment of breast cancer.
ABSTRACT
Objective To investigate the value of serum CEA and CA15-3 in the evaluation of breast cancer chemotherapy and prognosis.Methods 63 breast cancer patients were retrospectively analyzed from May 2011 to June 2012 in our Hospitals as breast cancer group,according to the situation of survival would be divided into survival group(n=42) and death group(n=21) and select indicators for outpatient medical normal crowd 63 cases as normal group.Serum levels of CEA and CA15-3 were measured by fluorescence immunoassay for 4 years.The prognosis of all patients was analyzed statistically.Results Serum level of CEA and CA15-3 in Ⅳ period breast cancer patients was obviously higher than Ⅲ period,the difference was statistically significant(P＜ 0.05).Chemotherapy efficient of CEA,CA15-3,CEA and CA15-3 express in negative group were obviously higher than positive group,the difference was statistically significant(P＜0.05).All patients were followed up for 1 to 4 years with an average follow-up time of 3.63 years and 42 patients survived for more than 4 years.CEA positive group patients of 4 years survival rate(55.26％) was obviously lower than negative group(84.00 ％),the difference was statistically significant(P＜0.05).CA15-3positive group patients of 5 years survival rate(52.78％) was obviously lower than negative group(85.19 ％),the difference was statistically significant(P＜ 0.05).CEA and CA15-3 positive group patients of 5 years survival rate (52.38％) was obviously lower than negative group (95.24％),the difference was statistically significant (P ＜ 0.05).Before treatment the serum CEA and CA15-3 level Survival groups was lower than death group,the difference was statistically significant(P＜0.05).Conclusion Detection of serum CEA and CA15-3 levels in patients with breast cancer before chemotherapy can provide reference data for chemotherapy efficacy and prognosis evaluation.Detection of breast cancer patients with chemotherapy before serum CEA and CA15-3 levels can provide reference for chemotherapy curative effect and prognosis assessment data.
ABSTRACT
Objective To investigate the value of serum CEA and CA15-3 in the evaluation of breast cancer chemotherapy and prognosis.Methods 63 breast cancer patients were retrospectively analyzed from May 2011 to June 2012 in our Hospitals as breast cancer group,according to the situation of survival would be divided into survival group(n=42) and death group(n=21) and select indicators for outpatient medical normal crowd 63 cases as normal group.Serum levels of CEA and CA15-3 were measured by fluorescence immunoassay for 4 years.The prognosis of all patients was analyzed statistically.Results Serum level of CEA and CA15-3 in Ⅳ period breast cancer patients was obviously higher than Ⅲ period,the difference was statistically significant(P＜ 0.05).Chemotherapy efficient of CEA,CA15-3,CEA and CA15-3 express in negative group were obviously higher than positive group,the difference was statistically significant(P＜0.05).All patients were followed up for 1 to 4 years with an average follow-up time of 3.63 years and 42 patients survived for more than 4 years.CEA positive group patients of 4 years survival rate(55.26％) was obviously lower than negative group(84.00 ％),the difference was statistically significant(P＜0.05).CA15-3positive group patients of 5 years survival rate(52.78％) was obviously lower than negative group(85.19 ％),the difference was statistically significant(P＜ 0.05).CEA and CA15-3 positive group patients of 5 years survival rate (52.38％) was obviously lower than negative group (95.24％),the difference was statistically significant (P ＜ 0.05).Before treatment the serum CEA and CA15-3 level Survival groups was lower than death group,the difference was statistically significant(P＜0.05).Conclusion Detection of serum CEA and CA15-3 levels in patients with breast cancer before chemotherapy can provide reference data for chemotherapy efficacy and prognosis evaluation.Detection of breast cancer patients with chemotherapy before serum CEA and CA15-3 levels can provide reference for chemotherapy curative effect and prognosis assessment data.
ABSTRACT
Objective To explore the diagnostic value of tumor markers of CEA,CA153,TPS,Fer and CYFRA21-1 level in postoperative metastasis of breast cancer.Methods After 3-year follow-up for 578 patients with primary breast cancer from 2012 to 2014,we chose 42 patients with metastasis as metastasis group,and another 42 cases without as non-metastasis group.Level of CEA,CA153,TPS,Fer and CYFRA21-1 was detected using chemiluminescence and the difference of CEA,CA153,TPS,Fer and CYFRA21-1 level in 2 groups was compared.Pearson correlation test analysis and ROC curve test were performed for data analysis.Results Serum CEA,CA153,TPS,Fer and CYFRA21-1 levelq6.11 ± 1.87)ng/mL,(26.97 ± 9.52) U/mL,(155.95 ± 22.03)U/L,(173.08 ± 19.87)ng/mL and (18.98 ± 7.33)ng/mL respectively increased in metastasis group when compared with those in non-metastasis group (5.33 ± 1.85)ng/mL,(23.34 ± 8.30)U/mL、(133.22 ± 19.09)U/L,(142.29 ± 22.59) ng/mL and (6.76 ± 1.59)ng/mLrespectively and the change of TPS,Fer and CYFRA21-1 was more obvious and the difference was statistically significant (P ＜ 0.05).There was no significant correlation among serum TPS,Fer and CYFRA21-lin metastasis group.The area under ROC curve of CYFRA21-1 was 0.903,followed by Fer (0.849) and TPS (0.791) and in the diagnosis of metastasis of breast cancer,CYFRA21-1 has great diagnostic value.Conclusions The increase of serum TPS,Fer and CYFRA21-1 level is closely associated with postoperative metastasis of breast cancer and CYFRA21-1 has great diagnostic value for monitoring postoperative metastasis of breast cancer.
ABSTRACT
Se presenta el caso clínico de una paciente de 21 años de edad, quien acudió a la consulta de Oncología del Hospital Gubernamental de Mbabane en Suazilandia por presentar un nódulo en la mama derecha con manifestaciones de dolor intenso desde hacía 1 mes. Fue remitida a la consulta de Cirugía donde le realizaron una biopsia con aguja gruesa, cuyo resultado indicó la presencia de un carcinoma ductal invasivo, clasificado en estadio IIIB al realizar los exámenes complementarios necesarios. La paciente fue trasladada a Sudáfrica para recibir quimioterapia neoadyuvante, con la cual obtuvo mejoría evolutiva clínica y humoral, evidenciada por la reducción del tumor y las cifras del marcador tumoral CA 15-3.
The case report of a 21 years patient who went to the Oncology service in the Government Hospital of Mbabane in Suaziland is presented. She had a nodule in her right breast with manifestations of acute pain for a month. She was referred to the Surgery service where she underwent a core-needle biopsy whose result indicated the presence of a ductal invasive carcinoma, classified in IIIB stage when carrying out the necessary complementary tests. The patient was transferred to South Africa to receive neoadyuvant chemotherapy, with which clinical and humoral response was obtained which was evidenced by tumor reduction and the values of the tumoral marker CA 15-3.
Subject(s)
Breast Neoplasms , Chemotherapy, Adjuvant , Carcinoma, Ductal, Breast/drug therapy , Biomarkers, TumorABSTRACT
PURPOSE: To assess the relationship between the kinetics of the serum CA15-3 level and the five-year disease-free survival rate of breast cancer patients. METHODS: The subjects of this study, 297 women who were diagnosed with breast cancer, were the subset of patients operated on at Kosin University Gospel Hospital from January 2008 to December 2010. We evaluated the change of serum CA15-3 levels during outpatient follow-up period. The changing patterns of serum CA15-3 level were divided into 5 categories; surge without decline, surge with incidental decline, decline without surge, decline with incidental surge, and no change. Clinicopathologic factors were evaluated for each group. RESULTS: The number of patients in surge without decline, surge with incidental decline, decline without surge, decline with incidental surge, and no changes groups were 30 (10.1%), 85 (28.6%), 80 (26.9%), 73 (24.6%), and 29 (9.7%), respectively. The clinicopathologic characteristics were not significantly different among these groups. The log rank test found that 5-year disease-free survival rate according to the kinetics of serum CA15-3 levels were significant (P = 0.004) particularly for the surge without decline group. CONCLUSION: According to the findings of this study, the surge without incidental decline pattern of serum CA15-3 levels during the follow-up period is associated with poor prognosis. Significant association was found among changing patterns of serum CA15-3 levels and breast cancer recurrence rate.
Subject(s)
Female , Humans , Breast Neoplasms , Breast , Disease-Free Survival , Follow-Up Studies , Kinetics , Outpatients , Prognosis , RecurrenceABSTRACT
Objective To evaluate the clinical value of early intervention of second-line treatment for advanced breast cancer patients who experienced elevated tumor marker without any evidence for progress on imaging after effective first-line treatment. Methods We recruited 42 metastatic breast cancer patients experiencing elevated tumor marker (CEA or CA-153) meanwhile, who had merely increased tumor markers again in regular review after effective first-line treatment. Patients were divided into two groups: 20 patients in treatment group were given second-line treatment (palliative chemotherapy); 22 patients in observation group insisted on regular follow-up without any changing of treatment strategy. We mainly evaluated PFSmarker , which was defined as the time between tumor markers increase and disease progression. Results CEA and CA-153 in patients with advanced breast cancer showed a tendency to decrease after first-line chemotherapy , which can be reduced again by second-line treatment while increased in regular review , and the observation group continued to rise until disease progressed. The PFSmarker in treatment group was 13.65 (6 ~ 24) months while that of the observation group was 8.18 (3 ~ 15) months. The difference of PFS between these two groups was statistically significant (P < 0.05) and the median time to disease progression in treatment group was significantly longer than that in observation group. Conclusions Early intervention of second-line treatment for advanced breast cancer patients who only experienced elevated tumor marker after effective first-line treatment could slow down disease progression and improve the quality of life.
ABSTRACT
Objective To investigate the expressions of carbohydrate antigen 19-9(CA19-9), carbohydrate antigen 15-3(CA15-3) and carbohydrate antigen 125(CA125) and their clinical significance in papillary thyroid carcinoma (PTC). Methods The expressions of CA19-9, CA15-3 and CA125 were detected by immunohistochemical MaxVision method in 80 cases of PTC and 80 cases of benign thyroid lesions (BTL), including 34 cases of nodular goiter, 26 cases of Hashimoto's thyroiditis and 20 cases of follicular adenoma. The relationship between expressions of CA19-9, CA15-3 and CA125 and the clinical pathological characteristics were analyzed. Results The expression rates of CA19-9, CA15-3 and CA125 in 80 cases of PTC were 85%, 100%and 43.8%respectively, compared with BTL, the difference was statistically significant (P 0.05). The sensitivity of CA19-9, CA15-3 and CA125 in the differential diagnosis of PTC and BTL were 85%, 100% and 43.8% respectively, and the specificity were 91.3%, 36.3%and 91.3%, respectively. Conclusion The expressions of CA19-9, CA153 and CA125 are helpful for the differential diagnosis of PTC and BTL.
ABSTRACT
Objective To detect and analyze the levels of preoperative serum carcino-embryonic antigen (CEA) and CA15-3 in early invasive breast cancer patients and their correlation with pathological parameters. Methods Electrochemical luminescence immunoassay (ECLI) technology was used to detect serum levels of CEA and CA15-3 in 223 cases of early invasive breast cancer patients, 109 patients with benign lesions, and 30 cases of heath control. Immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) were used to detect the estrogen receptors (ER), progesterone recepter (PR), and its HER-2 pathological indicators.Besides, the correlation of serum CA15-3, CEA levels and pathological parameters was analyzed. Results The serum CA15-3 and CEA levels of Breast cancer patients [(22.27±15.11) U/ml, (5.03± 0.49) μg/L] were significantly higher than that of patients in benign lesion group [(14.13±3.04) U/ml, (2.72± 0.11) μg/L] (P0.05). CEA positive rate of breast cancer group was significantly higher than that of benign lesions(13.5%vs. 3.7%, 26.5%vs. 1.8%, P<0.05). 30 cases of normal control group had no positive one. The joint monitoring sensitivity of CEA and CA15-3 breast cancer group was 9.4 %, the sensitivity was 0 in benign lesion group. There was significant difference (P < 0.05). Conclusion The changes of Serum CA15-3 and CEA levels in breast cancer patients can be considered as the judgment standard for early diagnosis, pathological staging, prognosis and clinical effect monitoring.
ABSTRACT
Objective:This study evaluates the relationship between carcino-embryonic antigen (CEA) and carbohydrate antigen 153 (CA153) continuous and remarkable reduction after chemotherapy and no-imaging progression in patients with advanced breast can-cer. Methods: Medical records of 93 patients who received chemotherapy in the Oncology Department of the General Hospital of Shenyang Military Command were included in the retrospective analysis. A total of 188 CEA and CA153 serum data were collected from response evaluations that included 105 CEA cases and 139 CA153 cases. Predictive validity of serum CEA and CA153 was as-sessed for diagnosing no-imaging progression. Results:CEA was continuously reduced by 10%, with sensitivity of 54.1%and specificity of 95%. CA153 was continuously reduced by 40%, with sensitivity of 19.1%and specificity of 96.6%. Conclusion:Serum CEA and CA153 could be considered as response evaluation tools when they are continuously reduced by at least 10%and 40%, respectively.
ABSTRACT
Objective The study is aimed to research into the effect of CD4+ T cells on patients with severe advanced breast cancer under radiotherapy that cannot be treated with surgery ,by observing the variation of CEA ,AFP ,CA125 and CA15‐3 before and after the radiotherapy applied .Methods We identified the CEA ,AFP ,CA125 and CA15‐3 densities in blood serum for a group of 38 patients with advanced breast cancer and a group of 30 normal people with chemiluminescence immune assay ,and we deter‐mined the CD3+ ,CD4+ ,CD8+ T percentage in peripheral blood and the ratio of CD4+ /CD8+ with flow cytometry .Results The group with normal CD4+ T percentage went through a decreased in CEA ,AFP ,CA125 ,CA15‐3 densities after the radiotherapy ,and the variation was significant(P<0 .05) .The group of people with abnormal CD4+ T percentage go through CEA ,CA15‐3 densities decrease after the radiotherapy ,and the variation was statistically significant(P< 0 .05) .Conclusion For those with advanced breast cancer and cannot be treated with surgery ,the influence of radiotherapy on CEA ,AFP ,CA125 ,CA15‐3 densities is significant in the group of patients with CD4+ T percentage ,adn has better therapeutic effect .
ABSTRACT
Objective To investigate the effect of acupuncture at Zusanli, Sanyinjiao and Danzhong on mammary estrogen receptor (ER) and progesterone receptor (PR) expressions in rats with dimethylbenzanthracine (DMBA)-induced mammary cancer. Methods One hundred and twenty female SD rats aged 6-8 weeks were randomized into a model group of 60 rats and a blank group of 30 rats. The model group received an oral gavage of DMBA for model making. The blank group received an oral gavage of equal volume of sesame oil. At 15 weeks after model making, the model group of rats was randomized into treatment and control groups. The treatment group received acupuncture at Zusanli, Sanyinjiao and Danzhong, and the control and blank groups, only the same grasp and release. After the completion of acupuncture treatment (twenty-seventh week), abdominal venous blood was taken and serum tumor markers were determined by electrochemiluminescence immunoassay. Tumor masses were counted and their shapes were recorded. The mass was taken and its height, maximum diameter and vertical diameter were measured using a 1 mm precision vernier caliper. Pathological changes in tumor tissues, and ER and PR positive areas and mean optical densities were observed under an Olympus optical microscope.Results There were statistically significant post-treatment differences in the average number and volume of mammary tumors between the treatment group and the control or blank group (P<0.01,P<0.05) and between the control and blank groups (P<0.01). There were statistically significant post-treatment differences in the concentrations of various tumor markers (CA724, CA125, CA199, AEP, CA15-3, CEA and CA50) between the treatment or control group and the blank group (P<0.01,P<0.05) and between the control and blank groups (P<0.01). There was a statistically significant post-treatment difference in CA15-3 concentration between the treatment and control groups (P<0.01). There were statistically significant post-treatment differences in ER and PR positive areas and mean optical densities between the treatment group and the control or blank group (P<0.01) and between the control and blank groups (P<0.01).Conclusions Acupuncture can reduce the occurrence of rat DMBA-induced mammary tumor (including the number and volumes of the tumors). The mechanism of its action may be related to decreasing the concentrations of tumor markers CA724, CA125, CA199, CA15-3, AEP, CEA and CA50 and especially to decreasing CA15-3 concentration, and ER and PR positive areas and mean optical densities.
ABSTRACT
BACKGROUND: Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-9 (MMP-9), and its specific tissue inhibitor - tissue inhibitor of metalloproteinases-1 (TIMP-1) may play an important role in the pathogenesis and spread of cancer. We investigated the plasma levels of M-CSF, MMP-9, and TIMP-1 in comparison with a commonly accepted tumor marker CA 15-3 in breast cancer patients and in control groups. METHODS: The cohort included 110 breast cancer patients in groups at stages I-IV. The control group consisted of 50 healthy volunteers and 50 benign tumor patients. Plasma levels of M-CSF, MMP-9, and TIMP-1 were determined by using ELISA, while CA 15-3 concentrations were determined by using chemiluminescent microparticle immunoassay (CMIA). RESULTS: The results showed significant differences in concentrations of the analyzed parameters and in levels of CA 15-3 between the groups of breast cancer patients and the two control groups. Diagnosis using these markers was equal to that using CA 15-3 in terms of sensitivity, predictive values of positive and negativetest results (PPV, NPV) and area under the ROC curve (AUC) in the studied groups. The diagnostic specificities of MMP-9, TIMP-1, M-CSF, and CA 15-3 showed equally high values (95%). The combined use of all tested parameters with CA 15-3 resulted in increased sensitivity, NPV, and AUC, especially in the combination of M-CSF with tumor markers (76%, 64%, and 0.8653). CONCLUSIONS: These findings suggest the tested parameters are useful in the diagnosis of breast cancer patients (except stage I), when combined with CA 15-3.
Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Area Under Curve , Biomarkers, Tumor/blood , Breast Neoplasms/diagnosis , Case-Control Studies , Macrophage Colony-Stimulating Factor/blood , Matrix Metalloproteinase 9/blood , Mucin-1/blood , Neoplasm Staging , Poland , ROC Curve , Sensitivity and Specificity , Tissue Inhibitor of Metalloproteinase-1/bloodABSTRACT
Objective To investigate the clinical value of CA125, CA153, HE4 joint detection in diagnosis of gynecological malignancies.Methods 70 cases of gynecological malignancies were selected from our hospital in 2013, 72 cases of benign gynecological diseases selected in the same period, and 70 healthy controls were selected. The expression levels of CA125, CA153 and HE4 were detected and statistically analyzed.Results The positive rate of serum CA125 in the gynecological malignancies group was higher than that in the benign gynecological disease group (p <0.05).The positive rate of serum HE4 in the gynecological malignancies group was higher than that in the benign gynecological disease group (p <0.01).The positive rate of CA125, CA153, HE4 joint detection in the gy-necological malignancies group (up to 72.9%) was also significantly higher than that in the benign gynecological dis-ease group (p <0.01).Conclusion is a single tumor marker with the highest sensitivity and specificity for diagno-sis of gynecological malignancies.CA125, CA153, HE4 joint detection can improve the positive rate of diagnosis of gynecological malignancies.
ABSTRACT
Objective:To evaluate the alternation of homocysteine (Hcy),folic acid(FA),CA15-3 and vitaminB12(VitB12) in patients with breast cancer and explore the correlation of them.Methods:The levels of FA ,CA15-3 and VitB12 in serum of 55 breast cancer and 35 benign tumor of breast and 50 controls were measured by electro-chemiluminescence immunoassay ( ECLI ) , the Hcy levels were measured by colorimetric method.Results:Compared with the normal controls and benign tumor of breast cancer ,there were some significantly changes in breast cancer patients including Hcy ,CA15-3 increased and FA ,VitB12 reduced ( P＜0.05 ) ,there were no significant differences in Hcy,FA,CA15-3,VitB12 levels between benign breast tumors and normal controls (P>0.05).Companied with TNM stage increased ,the levels of FA breast cancer groups decreased ,the levels of Hcy,CA15-3 increased.The correlation analysis showed that Hcy was negatively correlated with FA and VitB 12,(r=-0.341,r=-0.540),CA15-3 was negatively correlated with FA, CA15-3 was postively correlated with Hcy (r=0.378,r=-0.361).Conclusion: Serum Hcy,CA15-3,FA and VitB12 detection in patients with breast cancer are helpful in the severity judgment and regimen prognosis .
ABSTRACT
Circulating tumor markers have been paid more attention in the application of the treatment for breast cancer, the level of which has extended from protein to gene, including traditional tumor markers, HER-2 extracellular domain, circulating tumor cells, circulating tumor DNA (ctDNA), circulating RNA (ctRNA) and so on. As “liquid detection”, the detection of circulating tumor markers with real-time dynamic, easy operation, good reproducibility and other advantages are widely used in aiding early diagnosis, determining prognosis, prospectively predicting response or resistance to speciifc therapies, surveillance after primary surgery, and monitoring therapy in patients with advanced disease, The further study of circulating tumor markers may contribute to patient’s individual treatment.
ABSTRACT
Objective To investigate the diagnostic value of CA125 and CA153 for the combined detection of the disease in breast cancer patients.Methods 100 cases of breast cancer patients were selected as the breast cancer group,and the same period 100 cases of benign breast lesions were selected as the benign group,100 cases of normal healthy subjects were selected as the control group.The expression levels of CA125 and CA153 in the three groups were detected.Results CA153 and CA125 levels in the breast cancer group was (78.4 ± 23.76) U/mL,(71.3 ± 24.7) U/mL; The benign group CA153 and CA125 content were (13.4 ± 3.7) U/mL,(20.6 ± 12.4) U/mL;CA153 and CA125 in the normal control group content were (0.9 ± 0.8) U/mL,(19.3 ± 11.3) U/mL; CA153 and CA125 in the breast cancer group were significantly higher than those of the benign group and the normal control group,the difference was statistically significant (F =34.15,28.42,all P ＜ 0.05) ; CA153 and CA125 alone detected in breast cancer detection rate was 31.0 ％,24.0 ％,respectively,combined detection of CA153 and CA125 in breast cancer detection rate was 66.0％,CA153 and CA125 alone detected in breast cancer detection rate was significantly lower than the combined detection CA153 and CA125 in the breast cancer detection rate (F =8.21,P ＜ 0.05).CA153 and CA125 expression of breast cancer patients after treatment than that of before treatment significantly reduced,and compare the data with statistically significant (t =21.82,22.31,all P ＜ 0.05).Conclusion The clinical detection of CA125 and CA153 united can effectively improve the diagnosis of breast cancer effect,combined detection of higher sensitivity and specificity.Meanwhile,the combined detection of breast cancer clinical monitoring also ha ssome significance,which is worthy of clinical application.